A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Valladares Ayerbes, Manuel
Thumbnail
Estatísticas
Estatísticas
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/2745
PMID: 20127139
ISSN: 0167-6997
Rexistro completo
Servizos
Servizos
RISMendeleyLinksolver
Data de publicación
2011
Título da revista
INVESTIGATIONAL NEW DRUGS
Tipo de contido
Artigo